Krystal Biotech (KRYS) Assets Average (2017 - 2026)
Krystal Biotech (KRYS) posted quarterly Assets Average of $1.4 billion for Q2 2026, up 30.95% year-over-year from $1.1 billion in Q2 2025, and up 6.11% on a QoQ basis from $1.4 billion in Q1 2026.
Krystal Biotech (KRYS) Assets Average (2017 - 2026) Analysis & Trends
Krystal Biotech has reported Assets Average for 10 years, with the latest figure at $1.4 billion in Q2 2026.
- Assets Average for Q2 2026 came in at $1.4 billion, up 30.95% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.4 billion (up 30.95% YoY), and the FY2025 annual result was $1.2 billion, up 27.5% from the prior year.
- Assets Average improved to $1.4 billion in Q2 2026, from $1.4 billion in the prior quarter.
- Over five years, Assets Average peaked at $1.4 billion in Q2 2026 and troughed at $545.1 million in Q1 2023.
- A 5-year average of $901.9 million and a median of $860.7 million in 2024 frame the typical range for Assets Average.
- The widest annual swing landed in 2022, when Assets Average jumped 64.91%; it then declined 12.3% in 2023.
- A 5-year view of Assets Average shows it stood at $567.4 million in 2022, then surged by 41.76% to $804.4 million in 2023, then climbed by 26.7% to $1.0 billion in 2024, then gained by 26.29% to $1.3 billion in 2025, then increased by 12.58% to $1.4 billion in 2026.
- Per Business Quant data, the three most recent Assets Average figures were $1.4 billion in Q2 2026, $1.4 billion in Q1 2026, and $1.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 1.45 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.45 Bn |
| Mar 31, 2026 | 1.37 Bn |
| Dec 31, 2025 | 1.29 Bn |
| Sep 30, 2025 | 1.19 Bn |
| Jun 30, 2025 | 1.11 Bn |
| Mar 31, 2025 | 1.07 Bn |
| Dec 31, 2024 | 1.02 Bn |
| Sep 30, 2024 | 949.99 Mn |
| Jun 30, 2024 | 885.48 Mn |
| Mar 31, 2024 | 835.83 Mn |
| Dec 31, 2023 | 804.35 Mn |
| Sep 30, 2023 | 737.19 Mn |
| Jun 30, 2023 | 607.94 Mn |
| Mar 31, 2023 | 545.15 Mn |
| Dec 31, 2022 | 567.41 Mn |
| Sep 30, 2022 | 588.85 Mn |
| Jun 30, 2022 | 609.10 Mn |
| Mar 31, 2022 | 621.58 Mn |
| Dec 31, 2021 | 538.70 Mn |
| Sep 30, 2021 | 447.33 Mn |